Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the <scp>SURPASS</scp> J‐mono trial
In this post hoc analysis, non-glycemic and glycemic parameter improvements appeared differentially associated with weight loss, suggesting both weight loss-associated and -unassociated effects of tirzepatide.
Authors
- Masakazu Takeuchi (ORCID: https://orcid.org/0000-0003-3176-3118)
- Hirohito Sone (ORCID: https://orcid.org/0000-0003-1263-2817)
- Kazuya Fujihara (ORCID: https://orcid.org/0000-0001-6725-4169)
- Rina Chin (ORCID: https://orcid.org/0000-0001-5578-7814)
- Hanaka Mimura
- Tomonori Oura (ORCID: https://orcid.org/0000-0003-0872-8576)
Institutions
- Eli Lilly (Japan) (JP)
- Niigata University (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/jdi.14395
- Citations
- 4
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 4.66
Funders
- Eli Lilly and Company
- Mitsubishi Tanabe Pharma Corporation
- Eli Lilly Japan